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Resumo 
A angiogénese, processo pelo qual se formam novos vasos sanguíneos a partir de 
outros já existentes, desempenha um papel crucial não apenas em condições fisiológicas, 
mas também na progressão de diversas patologias tais como cancro, artrite reumatóide e 
retinopatia diabética. Desta forma, uma melhor compreensão dos mecanismos celulares 
e moleculares envolvidos na angiogénese é de extrema relevância. Os modelos 
matemáticos da angiogénese constituem uma ferramenta valiosa na previsão do 
crescimento vascular, em órgãos e tecidos sujeitos a diversos estímulos ou insultos, 
podendo, desta forma contribuir para o desenho de novas abordagens terapêuticas, 
dirigidas especificamente a alvos ou factores potencialmente identificados e descritos no 
modelo. Apesar da potencial relevância destes modelos, os dados quantitativos validados, 
que podem ser usados directamente para os parametrizar são escassos.  
São muitos os factores que estimulam e intervêm durante o processo de 
angiogénese, sendo o principal o Factor de Crescimento Endotelial Vascular (VEGF). Na 
verdade, este factor de crescimento tem sido amplamente descrito como responsável 
pela proliferação, migração e activação do fenótipo de tip cell nas células endoteliais (EC). 
Para além disso, o VEGF tem sido também associado a vasodilatação e aumento da 
permeabilidade de vasos já existentes, podendo desta forma contribuir para o complexo 
fenótipo de doença vascular.  
Assim, o principal objectivo deste trabalho foi caracterizar e quantificar o papel do 
VEGF na angiogénese. Para este efeito, numa primeira fase, começou-se por determinar a 
influência da densidade celular inicial na taxa de proliferação das ECs. Os resultados 
obtidos mostram que, independentemente da densidade inicial de células, estas seguem 
um crescimento exponencial. Além disso, foi determinada a taxa basal de secreção e 
consumo de VEGF, pelas ECs, bem como a sua influência na taxa de proliferação celular. 
Ao medir a quantidade de VEGF ao longo do tempo, quer na presença ou ausência de 
VEGF externo, concluiu-se que, independentemente da quantidade de VEGF adicionada 
ao meio, após uma diminuição inicial, a concentração deste mantém-se 
aproximadamente constante ao longo do tempo. Os resultados mostram também que as 
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concentrações de VEGF necessárias para desencadear uma resposta proliferativa em ECs 
são superiores às suas taxas de produção. Por outro lado, a exclusão de outros estímulos 
externos, além do VEGF, alcançada pela depleção de soro do meio de cultura, mostra que 
a adição de VEGF provoca, numa fase inicial, um rápido crescimento celular, após o qual o 
crescimento celular diminui, sugerindo que o VEGF por si só não é suficiente para 
sustentar a proliferação das ECs. Para além da proliferação, alterações dos níveis de VEGF 
durante a angiogénese podem modelar o comportamento das ECs, incluindo sprouting, 
que pode, por sua vez, condicionar a estrutura final da rede vascular. 
Os nossos ensaios de sprouting mostram que, dependendo da concentração em que 
está presente, o VEGF pode induzir sprouting ou proliferação das ECs. De facto os nossos 
dados demonstram que com baixas concentrações de VEGF, o sprouting é estimulado, no 
entanto quando presente em concentrações mais elevadas, a proliferação parece ser 
dominante sobre o processo de sprouting. 
Para validar os dados obtidos in vitro, analisamos a formação de estruturas 
vasculares em ensaios in vivo em função da concentração de VEGF. Os resultados obtidos 
mostram que concentrações mais elevadas de VEGF resultam em mais vasos e de maior 
calibre, que, frequentemente levam, em condições patológicas, à formação de vasos 
anormais e de elevada permeabilidade. Contudo, os nossos resultados mostram 
estruturas vasculares bem formadas e ausência de extravasamento, levando-nos a 
concluir que as concentrações de VEGF usadas permitem a formação de uma vasculatura 
funcional e fiável. 
Em resumo, os dados recolhidos neste trabalho vão permitir a parametrização da 
influência VEGF em processos essenciais para a angiogénese, incluindo a proliferação 
celular, migração, sprouting e formação de novos vasos sanguíneos. Além disso, estes 
resultados contribuem para melhorar os parâmetros matemáticos usados no modelo de 
angiogénese, permitidno, desta forma, aumentar a sua precisão e poder de 
previsibilidade. Assim, este estudo pode abrir novas perspectivas na avaliação da 
influência de factores que podem estar envolvidos na formação de vasos anormais 
geralmente associada a condições patológicas, fornecendo uma ferramenta poderosa 
para projectar novas estratégias terapêuticas na biologia vascular. 
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Abstract 
Angiogenesis, the process by which new blood vessels grow from existing ones, 
plays a crucial role not only in normal physiological conditions but also on the progression 
of several diseases such as cancer, rheumatoid arthritis and diabetic retinopathy. 
Therefore, a better understanding of the cellular, molecular and mechanical events 
involved in angiogenesis is of utmost importance. Quantitative mathematical models for 
angiogenesis constitute a valuable tool in the prediction of vascular growth, and may 
provide a powerful instrument to design new therapeutic solutions. Despite its putative 
biological and pathophysiological relevance, the currently repository of validated 
quantitative data that can be directly used to parameterize predictive mathematical 
models of angiogenesis is scarce. The best characterized player in the stimulation of 
angiogenesis is Vascular Endothelial Growth Factor (VEGF). Indeed, this growth factor has 
been extensively described as a general activator of endothelial cells (ECs) proliferation, 
migration and activation of tip cell phenotype. Additionally, VEGF has been associated 
with vasodilation of the existing vessels an increased permeability of the vessel wall.  
Therefore, the aim of this work was to characterize and quantify the influence of 
VEGF in angiogenesis. 
For this purpose, we started by determining the influence of initial cell density in 
proliferation rates of HMEC. The results obtained show that regardless the initial cell 
density, cells have an exponential growth. Furthermore we established the basal rate of 
VEGF secretion and consumption, by ECs, as well as its influence in the cell proliferation 
rate. By measuring the amount of VEGF over time, either in the presence or absence of 
externally added VEGF, we concluded that regardless the amount of VEGF added to the 
medium, after an initial decrease in the concentration of VEGF remains approximately 
constant in time and also that VEGF concentrations necessary to trigger a proliferative 
response in the ECs are superior to the range of their own production. Furthermore the 
isolation of other external stimuli besides VEGF, by depletion of serum from the culture 
medium, shows that addition of VEGF triggers a rapid cell growth in an initial stage, after 
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which the cell growth decreases, suggesting that VEGF by itself is not enough to sustain 
ECs proliferation. 
In addition to the initial trigger, modifications in the levels of VEGF during 
angiogenesis can model the behaviour of ECs, including sprouting and determine the final 
structure of the vascular network.  
Indeed sprouting is strongly dependent on VEGF. Our sprouting assays show that, 
depending on its concentrations, VEGF can induce sprouting or proliferation. Indeed our 
data demonstrate that for low concentrations of VEGF, sprouting is stimulated, whereas 
for higher concentrations proliferation seems to be dominant over EC sprouting. 
To validate the data obtain in vitro we also analysed vascular formation in in vivo 
matrigel assays as a function of the concentration VEGF. The results obtained show that 
higher concentrations of VEGF results into more and larger calibre vessels, that in 
pathological conditions often leads to the formation of abnormal and leaky vessels. 
However our results show well-formed vessels and absence of leakage, leading us to 
conclude that the VEGF concentrations used allow the formation of a reliable and 
functional vasculature. 
In summary, the data gathered in this work allowed the parameterization of VEGF 
influence on processes essential for angiogenesis including cell proliferation, migration, 
sprouting and new blood vessel formation. Moreover, these results will allow the 
improvement of the mathematical model for angiogenesis, in terms of accuracy and 
predictability. Thus, this study may open new perspectives regarding the evaluation of the 
factors that might be involved in abnormal vessel formation usually associated with 
pathological conditions, providing a powerful tool to design new therapeutical strategies 
in vascular biology.  
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Introduction 
In small and simple animal species such as the worm Caenorhabditis elegans and 
the fruit fly Drosophila melanogaster, oxygen is capable of diffusing throughout their 
small body to all cells. However in larger species, a diffusion mechanism is not sufficient, 
and is essential a vascular network capable of distributing oxygen and nutrients and 
collect the products resulting from the metabolic activity of all cells in the organism. 
The importance of a well-organized and structured vascular network starts at early 
stages of embryo development where blood vessels provide the necessary oxygen and 
nutrients to support the proper development of the growing organs. Apart from their 
nutritive function, vessels also carry instructive trophic signals that regulate cell behaviour 
and promote organ morphogenesis.  
The primitive vascular network arises from endothelial cells (ECs) precursors, which 
share an origin with hematopoietic progenitors. These progenitors ECs organize 
themselves in blood clusters which then assemble into a primary capillary plexus by 
autonomous migration, aggregation and alignment, through a process known as 
vasculogenesis (Carmeliet, 2005a). This primitive early vascular network is progressively 
expanded and remodelled by vessel sprouting, branching, splitting and differential growth 
of vessels through a process named angiogenesis, into a highly organized and hierarchical 
vascular network. Nascent ECs sprouts become covered by pericytes (PCs) and smooth 
muscle cells (SMCs), which provide strength and allow regulation of vessel perfusion. 
The formation of new vessels during angiogenesis can occur by growing new 
capillaries from the existing vessels through sprouting angiogenesis (SA) or by dividing 
existing capillaries, in a process called intussusceptive angiogenesis (IA).  
While angiogenesis intervenes at the embryonic stage by altering the initial capillary 
network into a mature and vascular structure, it also plays a pivotal role in specific 
moments of adult life, being essential in physiological processes like ovulation, pregnancy 
and wound healing. Nonetheless, angiogenic progression is also critical to the onset and 
progression of a large variety of different pathological conditions. For example, the 
aggressive outgrowth of blood vessels is involved in cancer, rheumatoid arthritis, 
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atherosclerosis and diabetic retinopathy, whereas insufficient blood vessel formation is 
associated with scaring following myocardial infarction and chronic wound healing failure 
(Carmeliet, 2005a; Carmeliet and Jain, 2000). The neo-vessels resultant from an 
aggressive pathological process such as the one occurring in solid tumor growth, grow in 
an environment where there is an imbalance in the relative quantities of pro- and anti-
angiogenic factors that is not reversed. This imbalance leads to a highly disorganized 
vascular growth and to the failure of the vessel maturation process, resulting in the 
formation of fragile and leaky vessels, which are prone to rupture. Improving the 
knowledge about the cellular and molecular events in angiogenesis and the influence of 
the factors that stimulate or inhibit it may lead to better ways to control the nutrient 
delivery to tissues, and consequently the survival of the organism. 
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Molecular mechanisms of angiogenesis 
Until the moment several endogenous biochemical factors capable of stimulating or 
inhibiting angiogenesis were identified. Among them are growth factors/cytokines and 
their receptors, extracellular matrix (ECM) constituents, matrix-degrading enzymes and 
cell-cell or cell-matrix molecules. These molecules have been show to participate and 
regulate various biological processes, such as gene transcription and signalling pathways 
controlling cellular movement, proliferation and phenotype alteration.  
One of the most important growth factors in angiogenesis is Fibroblast Growth 
Factor (FGF), namely FGF-1 (acidic FGF) and FGF-2 (basic FGF). FGF is a pleiotropic 
mitogenic for growth and differentiation that acts on most cells derived from embryonic 
mesoderm and neuroectoderm, including fibroblasts, ECs and PCs. The cellular effects of 
FGFs, occur via specific binding to high-affinity receptors for FGF (FGFR), that triggers a 
signaling cascade that stimulates all major steps in the angiogenesis process. FGF is 
produced by various cells including macrophages and tumour cells and is further secreted 
into the ECM, where it is entrapped through the interaction with ECM proteins (Botta et 
al., 2000). At the early steps of angiogenesis, degradation of ECM permits the release of 
FGF that is further used by ECs to promote cell growth. There is an intricate interaction 
with other growth factors, such as Vascular Endothelial Growth Factor (VEGF), that results 
in a synergistic action in many EC functions (Zachary, 2005). 
VEGF, the best characterized player in the stimulation of angiogenesis, is associated 
with vasodilation of the existing vessels and increase permeability of the vessel wall. It is 
also a general activator of EC proliferation and mobility. VEGF is a highly conserved 
homodimeric glycoprotein which is present in various forms, that exhibit different 
biological roles: VEGF-A, VEGF-B, VEGF-C and VEGF-D, being VEGF-A the main member of 
the VEGF family. The alternative splicing of VEGF-A gene results in three primary VEGF-A 
isoforms, namely VEGF121, VEGF165 and VEGF189, each presenting different properties, 
including unique ECM binding affinities based on the presence or absence of heparin-
binding domains.  This variable affinity for the ECM results in a proper spatial distribution 
of VEGF-A in the ECM. For example, VEGF189 the full-length protein, forms a homodimer, 
and has a limited biologic activity because of their membrane localization as a result of 
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heparin-binding sites, something that can be altered by proteolytic cleavage of a 
fragment of the protein. On the other hand, VEGF165, a splice variant rather than a 
proteolytic product of the full-length clone, although it maintains some heparin-binding 
capacity, this isoform of VEGF can also readily difuse, likely accounting for the majority of 
the angiogenic stimulatory properties of VEGF. Lastly, VEGF121 is a diffusible splice 
variant of VEGF that can no longer bind to the ECM (Ferrara et al., 2003). Although VEGF-
A can bind both VEGF receptors 1 and 2 (VEGFR1 and VEGFR2), most of the data suggests 
that binding of VEGF-A to VEGFR2 accounts for the majority of the angiogenic stimulatory 
signal observed in vivo, being VEGFR1 a decoy receptor with limited signalling capacity 
(Ho and Kuo, 2007). VEGFR2, which is highly expressed in ECs, is a transmembrane 
protein, with kinase activity, that upon binding of VEGF undergoes dimerization and 
autophosphorylation of specific tyrosines in the cytoplasmic domain. Activated VEGFR2 
sets off an intracellular cascade leading to the activation of multiple cellular responses 
namely EC migration, proliferation, differentiation, survival, as well as the translocation of 
endothelial progenitor cells from their place of origin, the bone marrow, to the blood 
circulation, in addition to an increase of vessel permeability and dilation (Figure 1) (Blanco 
and Gerhardt, 2013; Ferrara et al., 2003).  
Another important player on angiogenesis is the Platelet-Derived Growth Factor 
(PDGF), which triggers a series of signalling pathways upon binding to PDGF receptors. 
This factor is mainly produced by platelets, fibroblasts, macrophages and ECs. In blood 
vessels, PDGF receptor can be found in PCs, SMCs and also ECs (Li et al., 2003). The 
signalling pathways triggered by PDGF, after the binding to its specific receptors promote 
proliferation and migration of PCs along angiogenic sprouts, which plays a central role in 
blood vessel maturation. Transforming growth factor-β (TGF-β) family comprises 
multifunctional cytokines whose effects are mediated by TGF-β receptors (TGFR) and 
includes cell proliferation, differentiation, migration, inflammation and survival of many 
cell types. However, the binding of TGF-β, to the TGFR, that constitutes a receptor-type 
serine/threonine kinases, can either promote or repress angiogenesis, depending on the 
cells it acts. Indeed when it recruits inflammatory cells that release VEGF, FGF and PDGF, 
TGF-β presents a pro-angiogenic effect. On the other hand, by regulating ECs proliferation 
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and the production of ECM proteases, and their inhibitors, by ECs, TGF-β may inhibit the 
initiation of angiogenesis, but is important in stabilizing immature blood vessels (Hillen et 
al., 2007).The angiopoietins (Ang) are ligands that mediate the communication of ECs 
with their surrounding mesenchyme by binding to an endothelial-specific receptor called 
Tie-2. Despite the receptor being always the same, different ligands can have opposite 
effects. Indeed, Ang-1 and Ang-4 activates the Tie-2 receptor while Ang-2 inhibits the 
Ang-1-induced Tie-2 phosphorylation, acting as an antagonist of Ang-1. The action of Ang-
1, through the activation of the receptor, has a chemotactic effect in EC, also promoting 
the recruitment of PCs and smooth muscle cells therefore playing a role in stabilizing and 
maintaining vascular integrity. The action of this factor has also been described in 
embryonic vascular remodelling, promoting cell survival, sprouting and tube formation, 
and reducing inflammation. On the other hand Ang-2, that competes with Ang-1 for 
binding to Tie-2, is involved in postnatal angiogenic and vascular remodelling events, 
detaching SMCs, loosening the interactions of ECs with PCs and the ECM and therefore 
allowing ECs to migrate. Considering this data, Ang-2 may induce vessel regression, 
however in concert with VEGF contributes to the progression of angiogenesis (Jones et 
al., 2001). Angiogenesis is an highly regulated process that involves the coordinated and 
orchestrated action and participation of many factors that promote and/or control the 
process. The interaction and equilibrium of these factors define how the process 
proceeds, through one of two types: sprouting or intussusceptive angiogenesis. 
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Figure 1. Schematic representation of angiogenic factors and receptors. Adapted 
from Zachary (2005). 
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Types of angiogenesis 
Intussuspective angiogenesis 
Intussusceptive angiogenesis (IA) (also named splitting angiogenesis) refers to the 
process characterized by the formation of so called intraluminal tissue pillars that arise 
from the invagination of the capillary walls into the vascular lumen, through a complex 
multistep process. It starts when the endothelial walls of the opposite sides of a vessel 
migrate towards each other forming an intraluminal pillar. The interendothelial junctions 
are reorganized and a central perforation is formed in the core of the pillar. In sequence, 
the pillar is invaded by PCs and myofibroblasts that deposit ECM. This pillar elongates in 
the direction of the vessel axis, leading to the generation of two parallel capillaries. Finally 
several pillars increase in size and fuse with each other, splitting up the initial capillary 
into new capillaries (Figure 2) (Burri and Djonov, 2002; Djonov et al., 2000).  
The basement membrane remains intact during the course of this process, 
preventing the bloods vessels from becoming leaky. In addition, endothelial migration 
and proliferation are kept to a minimum as the endothelial cells do not necessarily 
proliferate but rather increase in size and change their shape(Styp-Rekowska et al., 2011).  
This form of angiogenesis has been described in a wide range of developing tissues 
including in different developmental stages in the mammary gland, in developing 
glomeruli and in the ovary cycle (De Spiegelaere et al., 2012). 
IA is regulated by a combination of hemodynamic forces and molecular actors. 
Studies using the chick chorioallantoic membrane show that blood flow establishes a 
hierarchical vasculature system, comprising venules and arterioles from a pre-existing 
capillary plexus. Furthermore the experiments revealed an increase in IA in blood vessels 
in which the blood flow is enhanced by clamping their side branches. However is still 
unclear whether the effect of hemodynamics on IA is mainly induced by changes in 
hydrostactic pressure, by cyclic stretch, by shear stress or by a combination of all factors 
(Styp-Rekowska et al., 2011). 
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Besides hemodynamic forces, IA can be also regulated by molecular mechanisms 
but due to lack of more accurate experimental assays, the molecular mechanisms and 
players involved in the control of IA remain largely unknown.  
Sprouting angiogenesis 
Sprouting Angiogenesis (SA) (also called tubular morphogenesis or sprouting 
angiogenesis) refers to the process in which activated ECs branch out from an existing 
capillary (or venule), extending through the surrounding matrix to form a new vessel.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
The process of sprouting occurs with a known sequence of events: first the 
basement membrane on the site of branching is degraded, the PCs detach and 
interendothelial contacts are weakened. Consequently ECs migrate into the connective 
tissue and form an endothelial sprout. Next, proximal to the migrating front, lumen starts 
to form and contiguous tubular sprouts anastomose originating functional capillary loops. 
In parallel occur the synthesis of the new basement membrane and the recruitment of 
PCs. Although initially the blood vessel sprouting progress without cells division, the 
sustainability of the growth requires cell proliferation (Figure 3) (Adams and Alitalo, 
2007). 
Figure 2. Schematic illustration of a small capillary undergoing intussusceptive angiogenesis. The 
opposite walls of this capillary start to migrate to each other, an intraluminal pillar is formed, and the 
cellular junctions of the opposing endothelial cells are rearranged. Subsequently, further growth of the 
pillar leads to spitting of the blood vessel into two new vessels. Adapted from Adams and Alitalo (2007). 
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Blood vessel sprout 
The initiation of sprouting requires the specialization of EC into tip and stalk cells 
with different morphologies and functional properties. Tip cell is migratory and polarized, 
while stalk cells proliferates during sprout extension and forms the nascent vascular 
lumen (Gerhardt et al., 2003). 
Tip cells are specialized cells that respond to environmental stimuli directing the 
migration and consequently the direction of the sprouting. Although endothelial tip cells 
are characterized by their migration properties, with only a minimal proliferation activity, 
in contrast, endothelial stalk cells, present a high proliferation rate. Moreover, tip cells 
can be distinguishable from their neighbour stalk cells by the presence of extensive 
Figure 3. Schematic illustration of sprouting angiogenesis. (a) This process is controlled by the balance 
between pro-angiogenic signals (+), such as VEGF, and factors that promote quiescence (-), such as 
tight PC  (yellow) contact, certain ECM molecules or VEGF inhibitors. In conditions that favor 
angiogenesis, some ECs can sprout (green). (b) Sprouting requires motile and invasive activity, the 
modulation of cell–cell contacts and local matrix degradation. The signals for sprouting include VEGF 
gradients, attractive (+) or repulsive (-) matrix cues and guidepost cells in the tissue environment. EC–
EC junctions need to be maintained after lumen formation to prevent excessive leakage. (c) Adhesive 
or repulsive interactions that occur when tip cells encounter each other regulate the fusion of adjacent 
sprouts and vessels. (d) Fusion processes at the EC–EC interfaces establish a continuous lumen. Blood 
flow improves oxygen delivery and thereby reduces pro-angiogenic signals that are hypoxia-induced. 
Perfusion is also likely to promote maturation processes such as the stabilization of cell junctions, 
matrix deposition and tight PC attachment. Adapted from Adams and Alitalo (2007). 
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filopodia and the highly branched shape while moving as well as the expression of specific 
markers such as delta-like ligand 4 (Dll4), platelet derived growth factor-b (PDGF-b), unc-5 
homolog b(UNC5b), VEGFR2 and VEGFR-3/Flt-4, and low levels of Notch signalling activity 
(Claxton and Fruttiger, 2004; Gerhardt et al., 2003; Siekmann and Lawson, 2007). On the 
other hand, the stalk cells produce fewer filopodia, constitute tubes and branches and 
form a vascular lumen. They also form junctions with neighbour cells and produce the 
components of the basement membrane. The balance between migration of tip cells and 
the proliferation of stalk cells allows adequately shaped nascent sprouts (Geudens and 
Gerhardt, 2011).  
This phenotypic specialization of endothelial cells in tip or stalk cells is transient, 
reversible and dependent on the balance between pro-angiogenic factors such as VEGF 
and Jagged-1 (Jag-1), and suppressors of EC activity such as delta-like ligand 4 (Dll4)-Notch 
activity. 
As described above in some detail, the VEGF-A signalling pathway has been 
established as an essential regulator of angiogenesis. In ECs, this pathway is mainly 
mediated by the VEGF-A signalling receptor, VEGFR2, which regulates the mitogenic and 
chemotactic response of ECs to VEGF. Interestingly, the different cells that constitute the 
sprouting respond differently to the presence of VEGF. Tip cells are responsive to a 
gradient of VEGF, whereas stalk cells are regulated by VEGF concentration and respond 
increasing their proliferation (Gerhardt et al., 2003).  
The leading tip cell responds to a VEGF gradient migrating outward from the main 
vessel up the gradient. This process involves the VEGF induced formation and extensions 
of filopodia, through the activation of the Rho GTPase Cdc42 , as well as the expression of 
DII4 protein in the tip cells. Tip cell filopodia surface presents, besides the high levels of 
VEGFR2 to detect the chemotactic VEGF-A, integrins such as α1β1, α2β1, and the αv 
integrins to engage binding sites within ECM and facilitate migration along the scaffold 
(Hynes et al., 2002).  
While in tip cells the effect of VEGF relies on the activation of the VEGFR-2, 
accumulated in filopodia, in stalk cells, the effect occurs predominantly through the 
activation VEGFR1, induced by Notch signalling.  The presence of VEGFR1 reduces VEGF 
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ligand availability and is involved in guidance and limited tip cell formation as well as 
reducing tip cell outward migration. Consistently, the loss of VEGFR1 leads to an increase 
in sprouting and vascularization(Chappell et al., 2009; Chappell et al., 2011).  
Overall, an emerging sprout integrates information from local guidance cues 
including soluble factors, ECM components and cell-cell contacts to initiate and maintain 
a proper trajectory away from the parent vessel.  
The filopodia from tip cells extend and engage with those of a nearby tip cell to 
form a bridge and the formation of a new vessel. Sprout fusion may therefore result from 
filopodia interactions and adhesions, and this increased cell-cell contact potentially 
enhances Notch signalling to reduce tip cell motility and stabilize the connection for 
further maturation (Bentley et al., 2009). The stability of the sprouts is reinforced by the 
recruitment of PCs trough the release of PDGFβ by the tip cells (Adams and Alitalo, 2007).   
During the process of vessel elongation and maturation, the stalk cells proliferate in 
response to VEGF, form a lumen, produce components of the basement membrane and 
associates with PCs, creating a more stable structure and increasing the mass and surface 
of the nascent vessel.  
The establishment of blood flow requires the formation of a vascular lumen, which 
involves a complex molecular mechanism composed of endothelial cell repulsion at the 
cell-cell contacts within the endothelial cell cords, junctional rearrangement and 
endothelial cell shape change. Two different ways of lumen formation have been 
described: cell hollowing and cord hollowing. By cell hollowing ECs creates the lumen 
through the coalescence of vesicles/vacuoles intracellularly. These vesicles carry apical 
markers helping to distinguish the future luminal membrane from the basal membrane of 
ECs. Once the cell is “hollowed”, intracellular vacuoles in ECs fuse by exocytosis, opening 
the cell to the exterior at both ends to a membrane-bound lumen (Kamei et al., 2006; 
Tung et al., 2012). In the model of cord hollowing, lumen is generated extracellularly 
without cell loss when an external cue signals for polarization, and surfaces in contact 
with the ECM accumulate basal markers whereas apical markers move near to cell-cell 
junctions at the central axis via vesicles. This vesicles fuse at the central axis, separating 
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the cell surfaces leading to the formation of a lumen continuous within itself and the 
parent vessel (Lammert and Axnick, 2012; Tung et al., 2012).  
The generation of a lumen is critical for stabilization of the newly formed vessel and 
the maintenance of the existing vasculature. Improved oxygen delivery lowers local 
VEGFA production, decreasing ECs migration and proliferation. 
During differentiation, transition from active sprouting to quiescent ECs, the tip cell 
adopts a “phalanx” phenotype, characterized by lumenized, non-proliferative, and 
immobile state of the cells that promotes vessel integrity and stabilization of the 
vasculature through an increased cell adhesion and low response to VEGF. 
Moreover the recruitment of mural cells (PCs and SMCs) and the deposition of ECM 
proteins into the subendothelial basement membrane also promote vessel maturation 
and quiescence.  During this phase a major role is played by angiopoietins (Ang-1 and 
Ang-2), which results in the development of the simple endothelial tubes into a more 
elaborate vascular network composed of several cell types. The angiopoietins contribute 
to the maintenance of vessel integrity through the establishment of appropriate cell-cell 
and cell-matrix connections (Thurston, 2003). 
After the formation of the vascular network the reorganization process starts, 
conducted by blood flow.  The hemodynamic stimuli caused by shear stress determines if 
the vessel regress, in cases of low flow or the adaptation of the size of the lumen, and the 
remodeling of the ECM (Song and Munn, 2011).  
Angiogenesis is a highly dynamic process and changes in the local balance between 
pro- and anti- angiogenic factors may lead to the elimination (pruning) of the new 
connections or the appearance of new ones.  
Tip and stalk cell dynamics 
This phenotypic specialization of endothelial cells in tip or stalk cells is transient, 
reversible and dependent on the balance between pro-angiogenic factors such as VEGF 
and Jagged-1 (Jag-1), and suppressors of EC activity such as delta-like ligand 4 (Dll4)-Notch 
activity. This dynamic of the molecular mechanisms that regulate tip-stalk cell selection is 
proven by the competition of ECs for the tip cell position (Jakobsson et al., 2010). The tip 
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cell has higher VEGF signalling than its neighbours, and Notch signalling controls the 
status of VEGF signalling among neighbouring cells.  
The Notch signalling is a highly conserved pathway essential in a diversity of 
processes, such as cell fate, proliferation and differentiation, playing a crucial role in 
vascular development (Gridley, 2010; Holderfield and Hughes, 2008). Notch-1 and Notch-
4 and three Notch ligands, Jag-1, Delta-like1 (Dll1), and Dll4 are expressed in ECs, where 
they participate in the induction of arterial cells fate as well as in the selection of 
endothelial tip and stalk cell phenotypes during SA (Blanco and Gerhardt, 2013; Gridley, 
2010; Roca and Adams, 2007) . Since the Notch receptors and ligands are all trans-
membrane proteins, Notch signal transduction pathway requires cell-cell contact. The 
Notch receptors, which are located at the cell surface, bind to ligands on adjacent cells, 
initiating the cleavage of the Notch intracellular domain and the activation of pathways 
regulated by Notch signalling. Evidence suggest that during angiogenesis the Notch-
mediated lateral inhibition, achieved when a cell expressing the highest levels of ligand 
activates Notch in the surrounding cells, is important not in endothelial cell fate decisions, 
but in regulating tip and stalk cell phenotypes during angiogenesis (Blanco and Gerhardt, 
2013). 
While the activation of the Notch signalling inhibits sprouting, impairment in ECs of 
this pathway induces tip cell phenotype (Hellstrom et al., 2007). Cells with low Notch 
activity have high VEGFR2 and low VEGFR1 expression, which results in higher levels of 
Dll4 expression and, hence through a higher production of DII4 than in the neighbouring 
cells, an increased ability to suppress its neighbouring cells from becoming tip cells. ECs 
with higher levels of VEGF increase Dll4 expression which further increases the cell 
sensitivity to VEGF, and this cell becomes the tip cell selected for outward migration for 
the original vessel (Jakobsson et al., 2010; Ribatti and Crivellato, 2012). The stalk cells 
have high levels of Notch signalling activity and elevated expression of Jag-1. The ligand 
Jag-1 antagonizes Dll4 activity, reducing the induction of Notch signalling in the adjacent 
tip cell, which therefore maintains its response to VEGF stimulation and continues to 
migrate to establish a new vessel (Benedito et al., 2009).  Cells dynamically compete for 
the tip position based on differential VEGFR levels, as cells with higher VEGFR signalling 
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express higher levels of DII4 and therefore inhibit their neighbour cells (Blanco and 
Gerhardt, 2013; Claxton and Fruttiger, 2004; Lobov et al., 2007). In this context, a refined 
feed-back mechanism between VEGF and Notch/Dll4 signalling pathways is established 
and a cross-talk between these pathways is essential for a proper vascular network 
formation (Figure 4).  
 
  
Figure 4. Tip/stalk cell specification during sprouting angiogenesis. During sprouting angiogenesis, 
VEGF and Notch signalling pathways are implicated in the specification of tip and stalk cells in the 
vascular endothelium. VEGF interacts with VEGFR2, expressed at the surface of the endothelial cells of 
the quiescent vessels. Under VEGF stimulation, Dll4 expression is up-regulated in the tip cells. In turn, 
Dll4 ligand activates Notch signalling in the stalk, consequently suppressing the tip cell phenotype. 
Notch signalling activation reduces VEGFR2 expression and increases VEGFR1 levels as well as the 
expression of different Notch target genes. In contrast, the tip cell receives low Notch signalling, 
allowing high expression of VEGFR2, but low VEGFR1. Contrary to Dll4, Jagged1 ligand is expressed by 
the stalk cells antagonizing Dll4–Notch signalling in the sprouting front. Adapted from Blanco and 
Gerhardt (2013). 
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The process of angiogenesis is extremely complex involving hundreds of proteins 
that regulate transcription and participate in signalling pathways controlling cellular 
movement, proliferation and phenotype alteration. Given its importance in a high variety 
of physiological and pathological processes angiogenesis has been a focus of research, 
including mathematical modelling. The ability to predict the formation and growth of a 
vascular bed provides and improves the current understanding of fundamental aspects of 
angiogenesis, constituting a valuable tool in the prediction of vascular growth, motivating 
the exploration of new therapeutic solutions. Combined experimental and theoretical 
approaches inevitably lead to a better understanding of how the mechanical cues, 
signalling pathways and factors interact to control angiogenesis in a pathological scenario. 
However there is a substantial lack of published data that can be used to parameterize 
quantitative models of angiogenesis.  
Angiogenesis is a widely studied theme and experimental studies have revealed the 
role of many different factors driving the formation of vascular networks, in physiological 
or pathological situations, however innumerable other processes, remain to be explained.  
The lack of full understanding on the biological process means that is difficult to modulate 
this process in a biological accurate form. Considering that, we focus in sprouting 
angiogenesis since it is the most studied type of angiogenesis where the biological and 
mechanical processes are more clearly identifiable.  
This work had the aim of quantifying vascular growth, and other processes 
associated with it, such as endothelial cell proliferation, VEGF consumption/production 
and formation of sprouting and vascular structures in vitro and in vivo. The data gathered 
by this project can be used by different groups in the task of constructing mathematical 
models of angiogenesis with predictive capabilities. We took advantage of existing 
protocols for qualitative and quantitative angiogenesis experiments to create this 
repository of quantitative data.  
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Material and methods 
Cell culture 
The human dermal microvascular endothelial cell line (HMEC-1, refered to hereafter 
as HMEC) (Ades et al., 1992) was developed by the Center for Disease Control and 
Prevention (Atlanta, GA, USA) and kindly provided by Dr. João Nuno Moreira. HMEC line 
was cultured in RPMI (Roswell Park Memorial Institute) 1640 medium supplemented with 
10% heat-inactivated fetal bovine serum (FBS), antibiotics (100 U/ml penicillin, 100 μg/ml 
streptomycin), GlutaMax (1x), 10ng of epidermal growth factor/mL (Benton-Dickinson, 
Bedford, MA, USA) and 1µg hydrocortisone/mL (Sigma-Aldrich, St. Louis, MO, USA). All 
media, GlutaMax and antibiotics were purchased from Invitrogen (Carlsbad, CA, USA). The 
cells were maintained at 37oC in a humidified chamber with 5% CO2. 
Cell counting assays  
After cell confluence has been reached the culture medium was changed and cells 
were left overnight in medium without serum to induce G0 synchronization. 
Cells were then seeded at the plating densities indicated inside 24 well culture 
dishes with 1mL medium containing no serum or either 2% or 10% of FBS. When 
indicated, cells were treated with recombinant VEGF165 (R&D Systems, Minneapolis, MN, 
USA). The evolution of cell density was followed by cell counting realized at successive 
intervals. Medium was removed and stored at -20oC for posterior VEGF quantification, 
and the cells were gently rinsed with phosphate buffered saline (PBS) solution. Then, all 
adherent cells were incubated in trypsin/EDTA solution at 37oC for 2 minutes. After 
suspension in fresh medium and mechanical dispersion adherent alive cells were counted 
using a TC10™ Automated Cell Counter (BioRad, Hercules, CA, USA). The automated cell 
counter was chosen after validation of the method through comparison with manual cell 
counting.   
Counting assays have been conducted without substitution of the cell culture 
medium and were performed in duplicates. 
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Determination of VEGF levels in supernatants 
The concentration of diffusible VEGF in the cell culture supernatants was measured 
by quantikine enzyme-linked immunosorbent (ELISA) assay kit using a monoclonal 
antibody direct against human VEGF, according the manufacturer’s protocol (R&D 
Systems, Minneapolis, MN, USA). Briefly, cell culture supernatant samples or standards 
were added to a 96-well plate, previously coated with a mouse monoclonal antibody anti-
human VEGF and incubated for 2 hours at room temperature. Subsequently, samples 
were aspirated and wells washed three times. In the last wash step, plate was inverted 
and blotted against clean paper towel to efficiently dry the wells. Wells were then 
incubated with a biotinylated goat anti-human VEGF antibody for 2 hours at room 
temperature. After incubation, wells were aspirated and washed three times, as 
mentioned before. Subsequently, wells were incubated with Streptavidin horseradish-
peroxidase for 20 minutes at room temperature. After incubation, wells were aspirated 
and washed three times, as mentioned before. Next, wells were incubated with the 
substrate solution, which is a 1:1 mixture of a hydrogen peroxide solution and a 
tetramethylbenzidine chromogenic solution, for 20 minutes and protected from light. The 
reaction was stopped by adding 2N (g/L) of H2SO4. Absorbance was measured at 450 nm, 
with wavelength correction at 570 nm, on a Biotek Synergy HT spectrophotometer 
(Biotek, Winooski, VT, USA), using the Gen 5 software to monitor the results (Biotek, 
Winooski, VT, USA). 
Endothelial sprouting assay 
Endothelial sprouting was assessed by a modification of the procedure described in 
Nakatsu et al. (2007). Briefly, microcarrier beads coated with gelatin (Cytodex® 3; Sigma-
Aldrich, St. Louis, MO, USA) were seeded with HMEC cells. When cells reached confluence 
on the beads, equal numbers of HMEC-coated beads were embedded in fibrin gel in 24-
well plates. For preparation of fibrin gels, bovine fibrinogen type I (Sigma-Aldrich, St. 
Louis, MO, USA) was dissolved in PBS in a concentration of 2.0mg/mL.  Aprotinin (Sigma-
Aldrich, St. Louis, MO, USA) was added at a concentration of 0.15 Units/mL, and the 
Material and methods 
 
 19 
solution was then filtered through a 0.22 µm-pore-size filter. The fibrinogen solution was 
supplemented with VEGF (R&D Systems, Minneapolis, MN, USA) in the indicated 
concentrations. As a control, fibrinogen solution without angiogenic factor was used. 
Next, after the beads were ressuspended in the fibrinogen solution at a concentration of 
~500 beads/ mL, the solution was transfered to 24-well plates and clotting was induced 
by the addition of 0.625 Units/mL of thrombin (Sigma-Aldrich, St. Louis, MO, USA). After 
clotting was complete, gels were equilibrated with RPMI-2%FBS at 37oC. Following 60 
minutes of incubation, the overlying medium was substituted by RPMI-2%FBS either 
alone or containing VEGF. 
Individual beads were imaged after 24 hours by using phase contrast. For each 
condition reported, at least n=3 independent experiments were performed, and ~10 
beads per device were imaged in each experiment.  
Matrigel plug assay 
Male Wistar rats (6 months old) were obtained from local breeding colonies 
maintained at the animal facility of the Faculty of Medicine – University of Coimbra by the 
group of Dr. Raquel M. Seiça (Physiology Group). The animals were subjected to a 
constant daily cycle of 12 hours of light and 12 hours dark with constant temperature (22 
- 24°C) and humidity (40 – 70%). Rats were given free access to water and to standard 
commercial pellet chow diet (AO4; Panlab, Barcelona, Spain). 
To model VEGF-driven in vivo angiogenesis, a subcutaneous matrigel plug assay was 
performed, as previously described {Malinda, 2009 #81}, with modifications. Briefly, 
growth factor reduced Matrigel (BD Biosciences, Bedford, MA, USA) was thawed at 4°C 
overnight to become liquid. After anesthetized, each rat was injected subcutaneously in 
the back, 1 cm off the midline, with 0,6 mL of liquid Matrigel supplemented with heparin 
(Sigma, St Louis, MO, USA), with or without VEGF (R&D Systems, Minneapolis, MN, USA) 
in the indicated concentrations.  
Seven days after implantation animals were anesthetized and injected through the 
jugular vein with an Evans Blue (Sigma-Aldrich, St.Louis, MO, USA) – PBS solution 
(100mg/Kg of body weight). Evans blue is a dye that combines with plasma albumin, 
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allowing for detection of functional vessels. Thirty minutes later, the animals were killed 
by cervical dislocation and the matrigel plugs were enucleated. 
Removed matrigel plugs were fixed in with 4% paraformaldehyde for 10 minutes, 
washed, embedded in OCT (Tissue-Tek, Histolab, Sweden) and stored frozen at -80°C until 
further analysis. Vascular density was determined by immunofluorescence on 5µm 
cryosections. The samples were permeabilized with 1% Triton X-100 (v/v) for 10 minutes 
and blocked with 5% Bovine Serum Albumin (BSA) for 1 hour prior the incubation with  a 
marker for endothelial cells,  primary antibody rabbit Anti- von Willebrand Factor (vWF) 
(Dako, Glostrup, Denmark)  overnight at 4°C. The samples were then rinsed three times 
with PBS and incubated with 1:5,000 DAPI (Invitrogen, Carlsbad, CA, USA) and 1:100 Alexa 
Fluor® 488-conjugated goat anti-rabbit (Invitrogen, Carlsbad, CA, USA) for 1 hour at room 
temperature. The samples were then washed with PBS and mounted with Mowiol® 4-88 
Reagent (Calbiochem, San Diego, CA, USA). The images were collected by confocal 
microscopy using a Zeiss LSM 710 Confocal microscope (Carl Zeiss MicroImaging GmbH, 
Jena, Germany).  
MTT cell viability assay 
After the treatments, HMEC cells seeded onto 24-well plates were washed twice 
with PBS and incubated with 0.5 mg/ml MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide; Invitrogen, Carlsbad, CA, USA] in RPMI-1640 for 2 hours at 
37°C in a cell culture incubator. Subsequently, supernatants were removed and the 
precipitated dye was dissolved in 300 μL 0.04 M HCl (in isopropanol) and quantified at a 
wavelength of 570 nm, with wavelength correction at 620 nm, using a Biotek Synergy HT 
spectrophotometer (Biotek, Winooski, VT, USA). 
BrdU incorporation colorimetric assay 
Cells seeded onto a 96-well plate were incubated with 5-bromo-2’-deoxyuridine 
(BrdU; Roche Applied Science, Indianapolis, IN, USA) labelling solution to a final 
concentration of 10 μM for 24 hours at 37°C. Subsequently, the labelling solution was 
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removed by taping-off the plate and 200 μl of FixDenat was added to the cells for 30 
minutes at room temperature. FixDenat induces cell fixation and DNA denaturation, 
making BrdU accessible for binding to an anti-BrdU antibody. Thirty minutes later, 
FixDenat was removed and 100 μl of peroxidase-conjugated anti-BrdU antibody (1:100 
dilution) was added per well. Antibody was incubated for 90 minutes at room 
temperature. Subsequently, cells were washed three times and the substrate solution 
tetramethyl-benzidine was added. Cells were then incubated at room temperature until 
colour development was sufficient for photometric detection (30 minutes). The entire 
procedure was performed as described by the manufacturer’s protocol (Roche Applied 
Science, Indianapolis, IN, USA) and absorbance was measured at 370 nm (reference 
wavelength at 492 nm) on a Biotek Synergy HT spectrophotometer (Biotek, Winooski, VT, 
USA). 
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Results 
Cell number as a function of time 
A main objective of this study is to establish how initial cell density, VEGF 
concentration and nutrient availability determine EC growth. 
We start by investigate how cell proliferation varies in function of initial cell 
number. 
To identify how plating cell number would affect cell proliferation estimation, 
plating experiments were performed with seeding of 1x104, 3x104 or 5.04x104 cells and 
cell counting was performed at successive intervals of 12 hours. The mean of the 
triplicates for each condition was calculated and plotted in the following graphics (see 
Figure 5 A, B and C).   
The data allowed us to determine if in these conditions the cells follow a simple 
exponential growth, how expressed in )(
)(
tN
dt
tdN
 , where α is the growth rate. If this 
is the case, then 

N(t)  N0e
 t  ln(N(t))  ln(N0) t , where N0 is the initial cell 
number, and so, the growth rate will  be the slope of the plot of ln(N(t)) as a function of 
time (see Figure 5). 
Indeed we observe that the data falls in approximately straight lines.  
Putting the three slopes together (Figure 5D) we can infer that the growth rate is

 0.01590.0011 /hour, being independent of the initial number of cells. 
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The cell growth is determined, among other factors, by the concentration of VEGF 
in the medium. Therefore, in order to establish if there is an important regulation of cell 
proliferation by the VEGF produced by the ECs themselves, we quantified the amount of 
VEGF present in the culture medium at various time points (Figure 6 A, B and C). 
 If VEGF is produced independently, then teNtN
dt
tdV  0)(
)(
  . The result of this 
equation 

V (t) V0 
N0

e t 1 V0 
N0




N(t) where γ is the VEGF production 
rate and V0 is the initial concentration of VEGF. Therefore, the slope of the line of VEGF 
concentration V(t) as a function of N(t) should give the ratio between the VEGF 
production rate of a cell, γ, and the cell growth rate α. 
Considering the data from these two experiments we can estimate the amount of 
VEGF produced per cell. As demonstrated in figure 6, the value for the slope 
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Figure 5. Cell number as function of time. 1x10
4
(A), 3x10
4 
(B) or 5.04x10
4 
(C) cells were platted and cell 
counting was performed at 12 hour interval, logarithm of cell number as function of time was plotted 
(dots). The cells followed an exponential growth and growth rate in function of initial cell number was 
calculated and is represent in (D). 
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
(3.3 0.5)105pg gives finally the production rate of 
610)1.12.5(  pg/hour/cell, 
also independent of the initial cell number. 
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Figure 6. VEGF in the medium as function of time and cell number. 1x10
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4
 (B) or 5.04x10
4
 (C) cells 
were platted and the medium was collected, at 12 hour interval, for VEGF quantification (dots). Slopes 
values of the three lines that allowed the calculation of VEGF production rate γ (D). 
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Cell number as function of VEGF   
Once we have established the ECs VEGF production rate, we investigated how these 
levels of VEGF influence cell growth. For this purpose, we evaluated cell number for 
different amounts of VEGF added to the medium. Importantly, the concentrations of 
VEGF used in this experiment were in the range of those observed in the previous 
experiment. To access those effects 1.5x104 cells were plated and VEGF was added to 
medium in the beginning of the experiment in the concentrations of 50, 100 and 200 
pg/mL. Medium without external VEGF was used as a control. The cell growth was 
followed by counting assay at successive intervals of 12 hours during 10 days. 
The graph presented in figure  7 shows that, independently of the concentration of 
VEGF tested, it is possible to observe an increase in the cell number as a function of time, 
with a similar pattern of increase, decrease and stabilization in the number of cells. 
Indeed, the number of cells over time does not significantly vary with the amount of VEGF 
added to the medium, at the order of magnitude of the amounts of VEGF produced by 
ECs. Since, the amount of VEGF in the medium changes over time, that is dependent on 
the balance between its production and degradation/consumption, we next quantified 
the levels of VEGF in the conditions 100pg/mL and 200pg/mL. The results presented in 
figure 8, show that regardless the concentration of VEGF added to the medium, the 
concentration decreases in the first hours, after which stabilizes. We observe again this 
behaviour when we analyse systematically the levels of VEGF in solution for cells 
incubated with different concentrations of VEGF. 
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Figure 7. Cell number as function of time and VEGF. 1.5x10
4 
cells were plated and VEGF was 
added to the medium in the concentrations of 50 (red), 100 (orange) and 200 pg/mL (yellow). 
Medium without external VEGF was used as a control (black). Cell counting was performed at 12 
hour interval.  Each data point represents the mean of cell number ± S.D.. 
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Figure 8. VEGF in the medium as function of time and initial concentration of 
VEGF. 1.5x10
4 
cells were plated and VEGF was added to the medium in the 
concentrations of 100 (orange) and 200 pg/mL (yellow), the medium was 
collected, at 12 hour interval, for VEGF quantification. Quantification was 
performed in the samples from the last time-points of the assay and VEGF 
concentrations were plotted in a graph (dots) Each data point represents the 
mean ± S.D.. 
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Cell number as function of VEGF and serum concentration 
The experimental approach used in the assays described above used complete cell 
culture medium that included serum. Since serum is known to contain various growth 
factors, including VEGF, a more accurate study of the effect of external added VEGF to cell 
proliferation, should be performed in cells cultured in the absence of serum. Moreover, 
under these conditions, the cells are all synchronized at the same stage of the cell cycle 
that additionally allows a more rigorous evaluation of the effect of VEGF in cell 
proliferation.  
The cell number chosen to perform this assays was the cell number that better 
translate for optimal cell density to maintenance of cell function evaluated through 
tubular formation assays (data not show).  
To address this question, 1.2x105 cells were plated in 24-wells plates, in complete 
medium (10% FBS) or medium without serum with different concentrations of VEGF: 0.5, 
1, 2.5, 5, 7.5 and 10 ng/mL; in the control no VEGF was added in the medium. The cell 
number was determined by cell counting at successive intervals of 12hours, after which 
the results were plotted in a graph ln(N(t)) as a function of time for different values of 
VEGF concentrations. The slopes obtained in these graphs represent the growth rates. 
The results obtained show that cells incubated in medium containing 10% of serum 
(complete medium), present a cell growth that follows a linear and exponential growth, 
Figure 9. This approach allows us to calculate the growth rate as function of VEGF 
concentration.  The results presented in Figure 9H demonstrate that all VEGF 
concentrations investigated, the number of cells increases over time. However, cells 
incubated with 1ng/mL of initial VEGF present the highest growth rate, with an increase 
of 60%, with respect to the growth rate in the absence of VEGF. 
To further determine the effect of serum, we used the same experimental 
conditions described above, with the exception of serum that is absent from the culture 
medium. In this case the amount of nutrients present in solution is can’t to sustain a 
constant growth rate. Therefore, not surprisingly, during the time of the experiment the 
growth rate decreases.  
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Therefore the simpler hypothesis that can be made is that the HMEC growth rate 
varies linearly in time: 

dN(t)
dt
 (1 t 2)N(t)
, with α1 negative. The solution for this 
equation is 

N(t)  N0e
1
2
t 2 2t
 ln(N(t))  ln(N0)
1
2
t2 2t
. Hence the plot of ln(N(t)) 
vs time can be fitted by a quadratic curve has represented in Figure 10. In Figure 10H is 
plotted the growth rate at 8 hours.  
In Figure 11is plotted in the same graph the growth rate either in the presence (blue 
markers) or absence of serum (red markers).  
 
  
Results 
 
 30 
 
  
10,5
11
11,5
12
12,5
0 20 40 60
ln
 (
N
(t
))
 
Time (hr) 
A 
10,5
11
11,5
12
12,5
0 20 40 60
ln
 (
N
(t
))
 
Time (hr) 
B 
10,5
11
11,5
12
12,5
13
0 20 40 60
ln
 (
N
(t
))
 
Time (hr) 
C 
10,5
11
11,5
12
12,5
0 20 40 60
ln
 (
N
(t
))
 
Time (hr) 
D 
10,5
11
11,5
12
12,5
0 20 40 60
ln
 (
N
(t
))
 
Time (hr) 
E 
9
9,5
10
10,5
11
11,5
12
12,5
13
0 20 40 60
ln
 (
N
(t
))
 
Time (hr) 
F 
0
0,02
0,04
-1 1 3 5 7 9 11
G
ro
w
th
 R
at
e
 (
h
r-
1 )
 
VEGF (ng/ml) 
H 
10,5
11
11,5
12
12,5
13
0 20 40 60
ln
 (
N
(t
))
 
Time (hr) 
G 
Figure 9. Cell number as function of time and VEGF. 1,2x10
5 
cells were plated in complete medium with 
different concentrations of VEGF. Cell counting was performed at intervals of 12hours and results of ln(N(t)) 
were plotted.  VEGF added to the medium (in ng/mL): 0 (A), 0.5 (B), 1 (C), 2.5(D), 5 (E), 7,5 (F) and 10 (G). The 
increase in the growth rate per hour as function of initial VEGF concentration was significant with 1ng/mL (H). 
*p<0,05. Each data point represents the mean ± S.D.. 
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Figure 10. Cell number as function of time and VEGF. 1,2x10
5 
cells were plated in medium without serum 
and different concentrations of VEGF were added to the medium. Cell counting was performed at intervals of 
12hours and results of ln(N(t)) were plotted. VEGF added to the medium (in ng/mL): 0 (A), 0.5 (B), 1 (C), 
2.5(D), 5 (E), 7,5 (F) and 10 (G). Cell growth rate per hour in function of VEGF concentration had no significant 
differences, each data point represents the mean ± S.D. (H). 
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Figure 11. Cell growth rate per hour in function of VEGF concentration. Growth rate in the presence (blue 
markers) or absence of serum (red markers). Each data point represents the mean ± S.D.. 
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Cell viability and proliferation 
The data from the counting assays were supplemented with MTT and BrdU assays. 
MTT assay is a colorimetric assay that is used to measure cellular metabolic activity 
and may, under defined conditions, reflect the number of viable cells present. MTT is 
added directly to the culture medium and is reduced by metabolically active cells to 
insoluble purple formazan dye crystals.   
To perform this assay HMEC cells were platted in similar conditions to the counting 
assays. As described previously, 1.2x105 cells were plated in 24-wells plates, in medium 
without serum or with 10% FBS, and supplemented with VEGF in the following 
concentrations: 0.5, 1, 2.5, 5, 7.5 and 10 ng/mL. In the control no VEGF was added in the 
medium. The assay was done 24 and 48 hours after platting, in duplicates. 
After normalization of the absorvance values with cell number media at that time-
point for each condition, results show that cell viability wasn’t significantly altered in any 
of the experimental conditions. As visible in Figure 12, the values of MTT are in or near 
the range of the values of MTT in the normal conditions (medium 10% FBS and without 
addition of VEGF, Figure12H in panel A and B) as visible the red lines that define the range 
of values covered by the error in this conditions. Similar results are obtained at 24 and 48 
hours.  
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Figure 12. Cell viability assay. 1,2x10
5 
cells were plated in medium without serum (A–G in both panels) and 
with 10% FBS (H-N in both panels). Different concentrations of VEGF were added to the medium (in ng/mL): 
0(A and H), 0.5 (B and I), 1 (C and J), 2.5(D and K), 5 (E and L), 7,5 (F and M) and 10 (G and N). MTT assay was 
performed 24 (Panel A) and 48hours (Panel B) after plating. Results were normalized by cell number and each 
data point represents the mean ± S.D.. 
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Figure 13. Cell proliferation assay. 2x10
4 
cells were plated in medium without serum (A–G in both panels) 
and with 10% FBS (H-N in both panels). Different concentrations of VEGF were added to the medium (in 
ng/mL): 0(A and H), 0.5 (B and I), 1 (C and J), 2.5(D and K), 5 (E and L), 7,5 (F and M) and 10 (G and N). BrdU 
incorporation assay was performed 24 (Panel A) and 48hours (Panel B) after plating. Results were 
normalized by cell number and plotted, each data point represents the mean ± S.D..  
The BrdU is a common reagent used for cell proliferation assays and for the 
detection of apoptotic cells. BrdU is a uridine derivative and a structural analog of 
thymidine, that is incorporated into DNA during the synthesis-phase of the cell cycle, 
phase S, as a substitute for thymidine, thereby serving as a marker for proliferation. That 
marker was detected by anti-BrdU antibodies, after cell fixation.  
For this assay the cells were platted in the same experimental conditions of serum 
and VEGF concentration described previously, for the counting and viability assays. 
However to the assay be performed in 96wells plates, the number of cells was adjusted to 
2.0x104 cells per well, to respect the cell density (number of cells per cm2), used in the 
other assays, namely cell counting and MTT. The assay was done 24 and 48 hours after 
platting, in triplicates. 
The results show that, after normalization of the absorvance values with cell 
number media at that time-point for each condition, results show that incorporation of 
BrdU was not significantly altered in any of the experimental conditions. As visible in 
Figure 13, the values of BrdU, similar to what happened in MTT assay, are in or near the 
range of the values of incorporation of BrdU in the normal conditions (medium 10% FBS 
and without addition of VEGF, Figure13H in panel A and B), as visible the red lines that 
define the range of values covered by the error in this conditions. Similar results are 
obtained at 24 and 48 hours. At 48 hours the incorporation of BrdU is higher in the 
conditions without serum, Figure 13B, in concordance with the results of growth rate in 
Figure 11, that showed that the growth rate in the conditions without serum were 
superior from the conditions with 10%FBS.  
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VEGF in the medium as function of cell number 
In an attempt to clarify the amount of VEGF produced by the cells, VEGF in the 
medium was quantified through ELISA assay in the samples without addition of external 
VEGF, without serum. 
In the condition of medium without serum and when no VEGF is added, the number 
of cells is approximately constant: 

N  (5.0 0.3)104  cells. Therefore, 

dV (t)
dt
  N0 , 
which implies that

V(t) V0  N0 t . And so, the graphic of the concentration of VEGF in 
the medium as a function of the time should fall on a straight line (Figure 14). 
From this slope we obtain a production of 

  (2.0 0.9)105  pg/hour, 
approximately 5 times larger than the production at 10%. However, the levels of VEGF 
observed in solution in this case are still very low to produce a significant alteration in the 
ECs growth rate. 
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Figure 14. VEGF as a function of time. 1,2x10
5
 cells were plated in medium without serum, the medium 
was collected and VEGF concentration was determined by ELISA assay. 
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VEGF in Solution 
Putting the data of all assays together we conclude that when the initial VEGF 
concentration is higher than 500 pg/mL we do not have the precision in our 
measurements to observe alterations in the concentration of VEGF in solution, i.e. to 
observe the production of VEGF by the endothelial cells. Hence, we observe an 
approximately constant amount of VEGF in solution.  
In the Figure 15 we plot the concentration of VEGF in solution as a function of the 
initial concentration of VEGF. For the larger concentrations we observe a very fast 
internalization of VEGF. No statistically differences were found in the internalization rate 
of VEGF when comparing medium with or without serum. 
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Figure 15. Concentration of VEGF in solution as function of initial concentration of VEGF. 
Representation of expected concentration if internalization rate were null (y=x) (black line). Error bars 
represent the error in the average of the measure concentration of VEGF in solution. 
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Sprouting assays 
One of the functions of VEGF is to modulate ECs sprouting. Therefore, in a 
subsequent stage of this work we evaluated the effects of VEGF concentration on VEGF-
induced endothelial sprouts. To address this question HMEC cells seeded on cytodex 
beads were cultured within 3D fibrin gel, containing different amounts of VEGF. All 
matrices were supplemented with aprotinin, a protease inhibitor typically added to slow 
fibrinolysis (Smith et al., 2007).  
As described in the literature, VEGF induces sprouting angiogenesis. In an attempt 
to quantify the influence of VEGF in endothelial sprouting we performed sprouting assays 
in fibrin gels using different VEGF concentrations diffuse in the medium: 0.5, 1 and 5 
ng/mL, medium without VEGF was used as a control. 
As observed in Figure 16, VEGF induce higher number and longer sprouts. It is also 
observable that in the higher concentrations of VEGF (Figures 16C and 16D) the number 
of cells near the beads is higher, suggesting an increase in the ECs proliferation as a 
function of VEFG concentration.  
However more assays are needed to perform a quantitative and standardized 
analysis.  
 
 
 
 
 
 
 
 
  
Results 
 
 38 
  
Figure 16. Sprouting induction by VEGF. Cytodex beads coated with HMEC cells were 
embedded within fibrinogen/thrombin polymerized gels and incubated without VEGF 
(A) or with different VEGF concentrations: 0.5ng/mL (B) 1ng/mL (C) 5ng/mL (D). 
Control Phase-contrast images were taken using an inverted light microscope 24 
hours after embebbing (100x of magnification) and images are representative of each 
condition.. 
A B 
C D 
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Matrigel plug assay  
Once we have established the effect of VEGF concentration in ECs growth rate, in a 
second stage of this work we intended to decipher the effect of VEGF on endothelial cell 
function in vivo. For this purpose, we used a matrigel plug assay, in which matrigel with 
heparin was supplemented with VEGF in different concentrations. Then, the matrigel with 
various concentrations of VEGF was injected subcutaneously in rats. After seven days, the 
animals were sacrificed and the vascularization of the matrigel evaluated by the presence 
of Evans blue, a dye known to combine with plasma albumin, which was injected 
systemically into the rat before the sacrifice. Furthermore, the ECs were identified using 
immunofluorescence staining for vWF, a specific marker of ECs. Representative images of 
each condition are present in Figure17. The results obtained show a low signal for Evans 
blue and vWF in control conditions, in which we injected matrigel without VEGF. on the 
other hand plugs carrying any of the VEGF concentrations showed a strong signal, thus 
demonstrating angiogenesis in vivo. Moreover it was evident an increase in the vessel 
density when comparing intermediate concentrations of VEGF, 10 and 35 ng/mL, Figure 
17B and 17C, respectively. Importantly higher caliber vessels are present predominantly 
in the highest concentration of VEGF, 60ng/mL (Figure 17D).  
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Figure 17. Vessel formation in vivo induced by VEGF. Wistar rats were injected with 
matrigel without VEGF (A) or containing different concentrations of VEGF: 10ng/mL 
(B) 35ng/mL (C) 60ng/mL (D). A week after matrigel implantation, rats were injected 
with Evans blue solution through the jugular vein and sacrificed.  Matrigel slices 5µm 
thickness were used to perform immunofluorescence using specific antibody against 
vWF. Matrigel were imaged by confocal microscopy and images are representative of 
each condition (400x magnification); vWF – green, Plasma albumin (Evans blue) – red, 
Nuclei (DAPI) – blue.  
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Discussion 
Understanding angiogenesis is essential to the potential control of the blood 
delivered to a tissue in order to prevent or promote its development, especially in a 
pathological condition. Considering the complexity of the angiogenesis process, the 
concurrence of sophisticated image-tracking systems and advanced mathematical 
models, would provide a relevant tool that integrates all the mechanical cues, signalling 
pathways and factors that interact and control angiogenesis. This would be particularly 
helpful to perform early prediction and diagnosis, and could help to define the proper 
therapies to be followed.  However the construction of biological accurate mathematical 
model is dependent of well-defined biological parameters. 
The final morphology of a vascular network depends on both phenomena which can 
occur at cell level, with activation and subsequent sprouting of new branches and on the 
large scale collective movements of the cells due to endothelial cell proliferation and the 
tissue properties. The sprouting angiogenesis constitutes a multifactorial and complex 
process, involving the orchestrated participation of hundreds of proteins that regulate 
transcription and participate in signal pathways involved in cell movement, proliferation 
and phenotype alteration. Among these factors is VEGF, a major regulator of angiogenesis 
that exerts its function upon binding to the major VEGF receptor, VEGFR2. VEGF-A is an 
important chemoattractant and mitogen factor, that a triple role in its vascular activity: 1) 
it is responsible for triggering vessel permeability, encouraging the deposition of proteins 
in the ECM and, consequently, activating the tip cell phenotype; 2) it also foments the 
migration of endothelial tip cells, which follow its gradient; and 3) fuels the proliferation 
of stalk cells and the survival of phalanx cells (Eilken and Adams, 2010; Gerhardt, 2008; 
Ho and Kuo, 2007). 
Given the vital importance of VEGF in angiogenesis, it is of utmost relevance to 
better elucidate the conditions and factors that govern and determine the effect of VEGF 
on proliferation and behavior of ECs in the presence of VEGF in vitro and in vivo. This 
would allow us to improve the mathematical model, in order to make more accurate and 
predictable regarding the angiogenic process.  
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One of the objectives of this work was to quantify and parameterize cell 
proliferation according to the ECs microenvironment. Cell proliferation, one of the most 
important biological phenomena occurring during angiogenesis, is very mutable and 
dependent of slightly changes in the cells microenvironment. One of the factors that is 
known to modulate the cell proliferation rate is the initial cell density.  
Therefore, in a first stage of this work we intended to determine the influence of 
initial cell density by evaluating cell proliferation rates using 3 different initial numbers of 
cells. Results obtained in these conditions demonstrate that cells have an exponential 
growth that is independent of the initial cell density. Moreover, this data enabled us to 
calculate a growth rate per cell is 0.0159±0.0011 per hour. Therefore the doubling time of 
a cell is 43.6±3.0 hours. 
Another important parameter that determines the growth rate of ECs is the 
presence of VEGF and its concentration. As a starting-point we define the amount of this 
factor in the medium over time, in the absence of external VEGF, and therefore we 
monitor the amount of VEGF produced by ECs. Through these results we could estimate 
the production rate of ECs in basal conditions, i. e. without any external stimuli, that is 
approximately 5.2 ±1.1 x10-6pg/hour/cell. Once we have established the basal rate of 
VEGF secretion, we further determine the influence of VEGF in the proliferation rate of 
ECs. 
To address this question we started by incubating the ECs with various VEGF 
concentrations in the order of magnitude of the amounts produced by ECs and 
determined in the previous experiment. Although VEGF constitutes an important 
mitogenic in angiogenesis, the results obtained is this study demonstrate that incubation 
of cells with external VEGF concentrations between 50 and 200pg/mL did not induce 
significant changes in cell proliferation when compared to basal conditions (without 
addition of VEGF). This result can be explained by the fact that the concentrations used 
are probably too low to influence in a significant way the ECs proliferation and 
consequently angiogenesis. Moreover, the simplicity of our in vitro model, involving a 
single type of cells, does not reproduce the in vivo biological environment of ECs, where 
they are in contact with other types of cells and external stimuli. Among these in vivo 
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stimuli is VEGF that during angiogenesis is produced, not only be ECs, but also by other 
cell types such as fibroblasts, inflammatory cells, and others often in response to 
increasing hypoxia via the HIF-1α pathway (Carmeliet, 2005b). Additionally, it is likely that 
in vivo local high concentrations of VEGF, confined to specific and restricted cell niches, 
differentially affects cell proliferation. These experiments indicate that at the observed 
cell densities, ECs behave independently, not influencing one another’s proliferation rate 
or VEGF production rate. Their growth is exponential and the growth rate depends on 
their medium, and not on cell density. This is certainly not the case for higher cell 
densities (see Figure 7), where we observe events of very high proliferation and cell death 
rates. This fact is not surprising considering that these cells form monolayers in culture, 
and that contacts between cells can regulate their number at high densities. The study of 
the proliferation rate at these high cell densities is out of the scope of this work. 
Considering these facts and the results from the previous experiment we decided to 
increase the concentrations used to test the correlation between VEGF and ECs 
proliferation. For this experiment we used a range of VEGF concentrations between 0.5 
and 10ng/mL. The results show that regardless the concentrations of VEGF, EC 
proliferation follows a similar exponential growth. Indeed we show that in this range of 
concentrations the mitogenic effect of VEGF in cell proliferation is not dose-dependent, 
that is in agreement with described for other cells types (Bernatchez et al., 1999; Rafiee 
et al., 2004), in others words, the increase in VEGF concentration is not always associated 
with an increase in growth rate. In fact with this experiment we demonstrate that VEGF 
elicits a biphasic proliferative response in cultured HMECs. Surprisingly, while the growth 
rate is higher in VEGF concentrations up to 1 ng/ml, and the response declined at 5-10 
ng/ml.  These observations suggest that there is a narrow window of desensitization to 
VEGF which may be important in vascular homeostasis. This is supported by the previous 
studies by Takagi et al., 1996, that showed a significant increase in VEGF expression in 
association with a transient decrease in VEGFR2 expression and VEGF binding. Based on 
these observations the authors proposed that when angiogenesis is not immediately 
needed, an increase from angiogenic stimulation of VEGF concentration may lead to 
downregulation of VEGFR2 thus protecting from angiogenic stimulation of VEGF. 
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Although our data consistently suggests that for the concentrations tested, the error 
associated with these experiments is high. Therefore more experiments are required not 
only to diminish the experimental error but also to test more concentrations of VEGF to 
perceive if the proliferation rate recovers or increases with higher concentrations (Cai et 
al., 2006).  
Since serum present in the cell culture medium contains VEGF and other factors 
that can interfere on the analysis of the effect of external VEGF, we further evaluate the 
effect of VEGF in cells incubated in the absence of serum. In these conditions, the 
concentration of VEGF that leads to a higher growth rate is 2.5ng/ml. However, with 
higher concentrations of VEGF, the growth rate diminishes, but is always higher than the 
in the absence of external VEGF.  However, when comparing growth rates of cells 
incubated either in the presence or absence of serum, for the same concentration of 
VEGF it is possible establish that, at 8 hours, the growth rate is superior in the absence of 
serum. Despite this fact the growth rates decreases after this time-point. In the absence 
of serum the external added VEGF constitutes the only source of growth factors present 
in the medium, and an abrupt increase in the levels of this factor prompt a rapid cell 
growth. After this initial period, VEGF is consumed, being the remaining VEGF together 
with the absence of nutrients from the serum not sufficient to sustain cell proliferation.  
Changes in cell growth can be due to variations in the concentrations of VEGF in the 
culture medium. To test this hypothesis we evaluated the levels of VEGF in the medium 
over time. The results obtained show that, regardless the amount of VEGF added to the 
medium, after an initial decrease in the concentration of VEGF remains approximately 
constant in time. Based on this data, we suggest that the abrupt decrease in the amount 
of VEGF present in the medium, in the first 2 hours after platting, is due to the binding of 
VEGF to its receptor, VEGFR, followed by internalization of the ligand. Moreover, it is 
conceivable to speculate that the effect of VEGF in cell behavior and proliferation is 
mostly after its binding to the receptor. 
Besides being an important mitogenic, VEGF also plays a role inducing and 
sustaining endothelial sprouting. For that reason we decided to perform sprouting assays 
to understand the influence of VEGF in the formation and extension of sprouting. In a first 
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approach we used ECs coated beads that were embedded in a fibrin gel, and incubated 
with different concentrations of soluble VEGF in the medium that diffuses equally in the 
fibrin matrix. In a qualitative analysis is possible to infer that VEGF induces more and 
longer sprouts, when compared with the control. However with the increase of VEGF 
concentration, the sprouts appear to loose linearity and direction, and the number of ECs 
around the carrier increases, likely due to the proliferation induced by VEGF. Taken 
together these results suggest that low concentrations of VEGF induces cell sprouting, 
however for higher concentrations of VEGF we observe a significant proliferation of ECs, 
with no effect on sprouting. 
As described before the balance between migration of tip cells and the proliferation 
of stalk cells is essential for the formation of adequately shaped sprouts (Geudens and 
Gerhardt, 2011). However each of this population of cells responds differently to VEGF. In 
our experimental conditions, the VEGF is soluble and is equally diffuse in the matrix, 
which does not allow a VEGF gradient. That fact compromises the direction of sprouting 
considering that the tip cell responds to a gradient, migrating outward from the starting 
point. However, stalks cells response to VEGF is not dependent of a gradient, but yet to a 
concentration of VEGF that induces their proliferation (Gerhardt et al., 2003), this might 
explain our results in which we show an increase in cell sprouting with low concentrations 
of VEGF, when a gradient is likely produced by the consumption of VEGF by the ECs, while 
for higher concentrations this growth factor induces proliferation of ECs. Besides soluble 
growth factors, properties of the ECM, like protein composition and stiffness, also plays a 
role in organizing ECs during sprouting morphogenesis (Davis et al., 2011; Mason et al., 
2013).  Recent studies have also shown that the mechanism whereby VEGF is presented 
from the ECM to ECs may affect the architecture of sprouting and consequently of the 
blood vessels formed (Anderson et al., 2011). Taking this into account, we are now 
performing sprouting assays altering the presentation form of VEGF, using for that VEGF-
coated beads or VEGF trapped in the matrix, that are distributed randomly in different 
densities. This will allow us to understand the positioning and directionality of sprouting 
under influence of different gradients created by the ECs trough the secretion of matrix 
metalloproteinases that degrade the matrix and release the VEGF. Strikingly due to the 
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magnetic properties of the VEGF-coated beads we will be able to manipulate their 
positioning.  
In the most part of this study we used cell culture systems to investigate various 
biological aspects of VEGF modulated HMEC proliferation and growth. Therefore, on a 
subsequent stage of this work we intended to validate the results obtained in vitro assays, 
using for this purpose in vivo experiments with Growth Factor Reduced Matrigel, in which 
VEGF, among other angiogenic cytokines, have been significantly depleted. Addition of 
recombinant VEGF caused higher recruitment of blood vessels to the Matrigel compared 
to PBS-loaded controls, thus demonstrating an angiogenic effect. Moreover, despite the 
increase in the recruitment and formation of the new vessels the vascular integrity was 
maintained and is not visible vessel leakage, translated by the absence of evans blue in 
the matrix, in any of the experimental conditions. Previous studies show that process of 
formation of new vessels is VEGF dose-dependent, and the phenotype of the new blood 
vessels is governed by the local concentration of this factor (Blanco and Gerhardt, 2013; 
Carmeliet, 2005b; Ferrara et al., 2003). Greater concentrations of VEGF produce more 
abundant blood vessels and exaggerate vessel abnormalities, whereas lower 
concentrations of VEGF drive less angiogenesis and promote thinner and more stable 
vessels. Our results lead us to conclude that the concentrations used in this experiment 
are within the range of concentrations that allow the formation of normal and functional 
vessels.  
The analysis performed in the sprouting and in matrigel assays was only qualitative, 
however in the future these assays will be complemented with a more methodic and 
accurate analysis that will allow the transposition of these results to quantitative data.   
In summary this work allowed us to test and understand better some biological 
phenomena already known that occur during angiogenesis. However the quantification 
and the parameterization these biological processes increase our knowledge about 
angiogenesis and will allow the improvement of a mathematical model of angiogenesis.   
The collaboration between biology and mathematical modeling can lead to a better 
understanding of the process of angiogenesis and properties of newly formed blood 
vessels will lead to even more informative assays and biomarkers. These in turn will help 
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in screening and evaluating of new, more efficacious drugs and other novel tools in 
vascular biology. Together these advances will further the exploitation of vascular 
abnormalities as targets for drug delivery and the control of blood vessel growth and 
regression in health and disease.   
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